DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Zim Laboratories Limited — Shareholders meeting

NSE 2 hrs ago·12 Aug 2026, 11:52 am

ZIM Laboratories

Zim Laboratories Limited has submitted its scrutinizer's report and announced the final voting results for its postal ballot to the stock exchange. This official filing confirms the outcome of the special resolution passed by shareholders, marking the formal conclusion of the company's governance process.

For investors, this update is a procedural milestone that signals the completion of the voting cycle. It provides clarity on shareholder sentiment regarding the specific proposal and ensures transparency in the corporate action. The company is now expected to proceed with the necessary steps to implement the approved resolution.

Investors should watch for the company's future announcements regarding the implementation of the approved resolution. This will detail the timeline and specific actions the company plans to take following the shareholder approval.